Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes. (Q53545029)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Marilena Gregorini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Mara De Amici

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Antonio Dal Canton

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Andrea Ranghino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Cristina Guidetti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Grazia Soccio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Maddalena Marasà

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Carmelo Libetta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Gianenrico Guida

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

12 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

published in

Transplant Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

32-36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17584600%20AND%20SRC:MED&resulttype=core&format=json

Long-term efficacy and safety of cyclosporine in renal-transplant recipients

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Sirolimus-associated hepatotoxicity in the kidney graft recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Sirolimus-associated acute respiratory distress syndrome in a renal transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Mycophenolate mofetil-induced neutropenia in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

The use of Mycophenolate Mofetil (Cellcept) in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Roles of PPARs in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

The mechanisms of action of PPARs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Peroxisome proliferator-activated receptors: nuclear control of metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

PPARs as drug targets to modulate inflammatory responses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Antiinflammatory properties of PPARgamma agonists following ischemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003

Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common gamma-chain and a lymphoid cell environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2007.03.003